The National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) recently issued a new suite of funding opportunities for neurotherapeutics development. The goals are to build a contiguous bridge from basic science, accelerate the advancement of promising projects to clinical testing with the contributions of multidisciplinary teams, and enhance han...

Dorsal root ganglion stimulation approval by the Food and Drug Administration: advice on evolving the process Timothy R. Deer & Jason E. Pope To cite this article: Timothy R. Deer & Jason E. Pope (2016) Dorsal root ganglion stimulation approval by the Food and Drug Administration: advice on evolving the process, Expert Review of Neurotherapeutics, 16:10, 1123-1125, DOI: 10.1080/14737175.2016.12...

Katja Heinicke, Tanja Taivassalo, Phil Wyrick, Helen Wood, Tony G. Babb, and Ronald G. Haller Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital, Dallas, Texas; Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Kinesiology and Physical Education, McGill University, Montreal, Quebec, Can...

Stroke is a devastating disease with few therapeutic options. Despite our growing understanding of the critical mechanistic events in post-stroke brain injury, the clinical translation of these findings has been less effective. A monumental hurdle to the field has been the inability of many systemically applied therapies to efficiently cross the blood brain barrier (BBB) and enter brain cells. ...

Epilepsy is a neurological disorder characterized by the recurrence of seizures. It affects 50 million people worldwide. Although a considerable number of new anti-epileptic drugs with reduced side-effects and toxicity have been introduced since the 1950s, 30% of patients remain pharmacoresistant. Although epilepsy research is making progress, advances in understanding the drug resistance have ...